ATE529535T1 - Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe - Google Patents

Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe

Info

Publication number
ATE529535T1
ATE529535T1 AT07024457T AT07024457T ATE529535T1 AT E529535 T1 ATE529535 T1 AT E529535T1 AT 07024457 T AT07024457 T AT 07024457T AT 07024457 T AT07024457 T AT 07024457T AT E529535 T1 ATE529535 T1 AT E529535T1
Authority
AT
Austria
Prior art keywords
gene expression
breast cancer
biopsy
tumor tissue
expression profiling
Prior art date
Application number
AT07024457T
Other languages
English (en)
Inventor
Joffre B Baker
Maureen T Cronin
Michael C Kiefer
Steve Shak
Michael G Walker
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28045456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE529535(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of ATE529535T1 publication Critical patent/ATE529535T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AT07024457T 2002-03-13 2003-03-12 Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe ATE529535T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36489002P 2002-03-13 2002-03-13
US41204902P 2002-09-18 2002-09-18

Publications (1)

Publication Number Publication Date
ATE529535T1 true ATE529535T1 (de) 2011-11-15

Family

ID=28045456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07024457T ATE529535T1 (de) 2002-03-13 2003-03-12 Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe

Country Status (9)

Country Link
US (9) US7081340B2 (de)
EP (9) EP3115470B1 (de)
JP (6) JP2005519624A (de)
AT (1) ATE529535T1 (de)
AU (1) AU2003253986A1 (de)
CA (2) CA2992643C (de)
DK (5) DK3115470T3 (de)
ES (5) ES2486265T3 (de)
WO (1) WO2003078662A1 (de)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972697A (en) * 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
US7125677B2 (en) * 1995-11-13 2006-10-24 The Salk Institute For Biological Studies NIMA interacting proteins
US6277566B1 (en) * 1998-02-13 2001-08-21 Phillip A. Beachy Method for identifying a hedgehog-mediated phosphorylation state dependent transcription factor
US20080085515A1 (en) * 2000-03-24 2008-04-10 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by detection of their nucleotide sequences on arrays
US20070298423A1 (en) * 2000-03-24 2007-12-27 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by specific amplification and detection of their nucleotide sequences on arrays
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7640484B2 (en) 2001-12-28 2009-12-29 Netapp, Inc. Triple parity technique for enabling efficient recovery from triple failures in a storage array
DK3115470T3 (en) * 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US7364846B2 (en) * 2002-10-11 2008-04-29 Molecular Devices Corporation Gene expression profiling from FFPE samples
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US20100022414A1 (en) 2008-07-18 2010-01-28 Raindance Technologies, Inc. Droplet Libraries
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
CA2527285A1 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005054466A2 (en) † 2003-07-25 2005-06-16 Ambion, Inc. Methods and compositions for preparing rna from a fixed sample
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
FR2861744A1 (fr) * 2003-11-05 2005-05-06 Biomerieux Sa Procede pour le pronostic du cancer du sein
EP1699936B1 (de) * 2003-12-23 2011-02-09 Genomic Health, Inc. Universelle vervielfältigung von fragmentierter rns
CA2552658A1 (en) * 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
WO2005087948A2 (en) * 2004-03-12 2005-09-22 The Queen's University Of Belfast Cancer treatment and assays for determining resistance to platinum-based chemotherapeutic agent
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
EP1737980A2 (de) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Genexpressionsmarker zur vorhersage des ansprechens auf chemotherapie
JP5690039B2 (ja) * 2004-06-04 2015-03-25 バイオセラノスティクス インコーポレイテッドＢｉｏｔｈｅｒａｎｏｓｔｉｃｓ，Ｉｎｃ． 腫瘍の同定
US20120258442A1 (en) * 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
WO2006017150A2 (en) * 2004-07-09 2006-02-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatiion Identification of markers in lung and breast cancer
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20060134663A1 (en) * 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2006052731A2 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
ATE477495T1 (de) * 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
JP2008534002A (ja) * 2005-04-01 2008-08-28 エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド 乳癌の分類に関する材料および方法
US8652786B2 (en) 2005-04-05 2014-02-18 The General Hospital Corporation Method for predicting responsiveness to drugs
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
CA2610752A1 (en) 2005-06-03 2006-12-14 Aviaradx, Inc. Identification of tumors and tissues
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8921102B2 (en) * 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
WO2007030611A2 (en) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System A calculated index of genomic expression of estrogen receptor (er) and er related genes
CA2623445A1 (en) * 2005-09-21 2007-03-29 Ccc Diagnostics, Llc Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
US7723112B2 (en) 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
EP2487261B1 (de) * 2006-01-05 2015-07-01 The Ohio State University Research Foundation Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von festen Krebsen
EP1984738A2 (de) 2006-01-11 2008-10-29 Raindance Technologies, Inc. Mikrofluidische vorrichtungen und verfahren zur verwendung bei der bildung und kontrolle von nanoreaktoren
CN101384903A (zh) 2006-02-09 2009-03-11 南佛罗里达大学 利用bcl-2水平的增高检测癌肿
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
CN101240331A (zh) * 2006-04-07 2008-08-13 甄二真 基于mEPHX基因多态性的皮肤美容保健方法
WO2007127458A2 (en) * 2006-04-28 2007-11-08 Nsabp Foundation, Inc. Methods of whole genome or microarray expression profiling using nucleic acids
EP4190448A3 (de) 2006-05-11 2023-09-20 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtungen
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) * 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
WO2008008284A2 (en) 2006-07-14 2008-01-17 The Regents Of The University Of California Cancer biomarkers and methods of use threof
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US20080118576A1 (en) * 2006-08-28 2008-05-22 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types
EP2061904A2 (de) * 2006-09-06 2009-05-27 Ortho-McNeil Pharmaceutical, Inc. Biomarker zur überprüfung der reaktion auf eine c-met-behandlung
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
ES2405654T3 (es) * 2006-09-21 2013-05-31 Nuclea Biomarkers Llc Perfiles de expresión asociados con el tratamiento con irinotecan
JP5041580B2 (ja) * 2006-10-17 2012-10-03 一般財団法人化学及血清療法研究所 仲介ポリヌクレオチド
US20080125358A1 (en) * 2006-10-26 2008-05-29 University Of Massachusetts Medical School Methods for Chk2 inhibitor patient selection
KR100862972B1 (ko) 2006-10-30 2008-10-13 한국과학기술연구원 휘발성 유기 화합물 검색용 바이오마커 및 이를 이용한유해성을 나타내는 휘발성 유기 화합물 검색 방법
WO2008063521A2 (en) * 2006-11-13 2008-05-29 The General Hospital Corporation Gene-based clinical scoring system
KR100886670B1 (ko) 2007-01-11 2009-03-04 김현기 유두갑상선암의 새로운 진단마커 및 진단방법
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008127719A1 (en) * 2007-04-13 2008-10-23 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to kinase inhibitors
EP2134875A2 (de) * 2007-04-13 2009-12-23 Brystol-Myers Squibb Company Biomarker und verfahren zur bestimmung der empfindlichkeit gegen modulatoren des vaskulären endothelialwachstumsfaktors 2
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2008150937A2 (en) * 2007-05-29 2008-12-11 Aivaradx, Inc. Real-time pcr
EP2167683A4 (de) 2007-05-31 2010-10-20 California Pacific Med Center Verfahren zur vorhersage oder diagnose einer magen-darm-störung oder -krankheit
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2583377T3 (es) 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
WO2009015299A1 (en) 2007-07-26 2009-01-29 California Pacific Medical Center Method to predict or diagnose a gastrointestinal disorder or disease
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
WO2009026128A2 (en) * 2007-08-16 2009-02-26 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
US8921114B2 (en) 2007-08-24 2014-12-30 Sysmex Corporation Diagnosis support system for cancer, diagnosis support information providing method for cancer, and computer program product
US9388457B2 (en) 2007-09-14 2016-07-12 Affymetrix, Inc. Locus specific amplification using array probes
US8716190B2 (en) 2007-09-14 2014-05-06 Affymetrix, Inc. Amplification and analysis of selected targets on solid supports
CA2699385A1 (en) * 2007-09-14 2009-03-19 Ventana Medical Systems, Inc. Prostate cancer biomarkers
AU2008307579A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2694154A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009048901A1 (en) * 2007-10-09 2009-04-16 University Of Washington Quantitative/semi-quantitative measurement of epor on cancer cells
ES2538362T3 (es) * 2007-10-16 2015-06-19 Ventana Medical Systems, Inc. Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C
WO2009055559A1 (en) * 2007-10-23 2009-04-30 University Of South Florida Method of predicting chemotherapeutic responsiveness of cancer
JP2011504093A (ja) 2007-10-26 2011-02-03 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 脆弱性ヒスチジン三連構造（ｆｈｉｔ）相互作用を同定するための方法およびその使用
EP2065473A1 (de) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH Verfahren zur Prognosebeurteilung und Vorhersage des Behandlungserfolgs von gynäkologischem Krebs
WO2009068423A2 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
CA2737137C (en) * 2007-12-05 2018-10-16 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
CA2723972A1 (en) 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
EP2288727B1 (de) * 2008-05-14 2013-07-10 Genomic Health, Inc. Vorhersageindikatoren des ansprechens von patienten auf eine behandlung mit egf-rezeptor-inhibitoren
US20110318732A1 (en) * 2008-05-28 2011-12-29 Singer Robert H Prediction of chemotherapeutic response via single-cell profiling of transcription site activation
CN102149827B (zh) 2008-06-11 2014-08-20 由卫生与公众服务部代表的美利坚合众国政府 MiR-26家族作为肝细胞癌和对治疗的应答性的预测性标志物的用途
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
SMT201700149T1 (it) 2008-09-20 2017-05-08 Univ Leland Stanford Junior Diagnosi non invasiva di aneuploidia fetale mediante sequenziamento
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
CA2741906A1 (en) * 2008-10-29 2010-05-14 William Beaumont Hospital Methods of using biomarkers
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
BRPI1007048A2 (pt) * 2009-01-15 2016-02-10 Lab Corp America Holdings método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
JP2012519170A (ja) * 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2425021A4 (de) * 2009-05-01 2013-03-06 Nuvera Biosciences Inc Index der genomexpression von estrogenrezeptor (er) und er-assozierten genen
WO2010135411A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of Colorado Aurora-a copy number and sensitivity to inhibitors
EP2278026A1 (de) * 2009-07-23 2011-01-26 Université de la Méditerranée Verfahren zur Vorhersage des klinischen Ergebnisses von Patienten mit Brustkarzinom
EP3461912B1 (de) 2009-09-09 2022-07-13 The General Hospital Corporation Verwendung von mikrovesikeln bei der analyse von nukleinsäureprofilen
WO2011038063A1 (en) 2009-09-28 2011-03-31 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
JP5964752B2 (ja) * 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法
EP2507396A4 (de) * 2009-12-01 2013-06-19 Precision Therapeutics Inc Auf mehrere wirkstoffe reagierende marker für brustkrebszellen
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
MX375138B (es) * 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
WO2011088137A2 (en) * 2010-01-12 2011-07-21 H. Lee Moffitt Cancer Center & Research Institute Bad pathway gene signature
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP4435111A1 (de) 2010-02-12 2024-09-25 Bio-Rad Laboratories, Inc. Digitale analytanalyse
US20130143753A1 (en) * 2010-03-01 2013-06-06 Adelbio Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
AU2011223655A1 (en) * 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110217297A1 (en) * 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
WO2011122859A2 (ko) * 2010-03-30 2011-10-06 서울대학교 산학협력단 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
US8597201B2 (en) 2010-03-30 2013-12-03 Siteselect Medical Technologies, Inc. Tissue excision device with a flexible transection blade
JP5553661B2 (ja) 2010-03-30 2014-07-16 シスメックス株式会社 癌の再発リスク判定方法
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
EP3508854A1 (de) * 2010-04-27 2019-07-10 The Regents of The University of California Krebsbiomarker und verfahren zur verwendung davon
EP2577291A4 (de) * 2010-05-26 2014-11-26 Expression Pathology Inc Urokinase-plasminogen-aktivator, protein/plasminogen- aktivator-hemmer vom typ 1 und assay zur überwachung ausgewählter proteinreaktionen
US20120053253A1 (en) 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
DE102010033575B4 (de) 2010-08-02 2016-01-14 Eberhard-Karls-Universität Tübingen Universitätsklinikum ASPP2-Splicevariante
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
EP2611941A4 (de) 2010-08-30 2014-01-22 Myriad Genetics Inc Gensignaturen zur krebsdiagnose und -prognose
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
CA2816603A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
EP2640368B1 (de) 2010-11-15 2020-12-30 The Ohio State University Research Foundation Mukoadhäsive systeme mit kontrollierter freisetzung
WO2012090073A2 (en) * 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012097368A2 (en) * 2011-01-14 2012-07-19 Response Genetics, Inc. Her3 and her4 primers and probes for detecting her3 and her4 mrna expression
WO2012109233A2 (en) * 2011-02-07 2012-08-16 Board Of Regents, The University Of Texas System Methods for predicting recurrence risk in breast cancer patients
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
EP2675819B1 (de) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
EP2683387A4 (de) 2011-03-07 2014-09-03 Univ Ohio State Durch mikro-rna-155 (mir-155) induzierte mutatorgenaktivität gegen entzündungen und krebs
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2012167142A2 (en) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Enzyme quantification
EP2726609A4 (de) * 2011-07-01 2015-03-04 Pinpoint Genomics Inc Verfahren zur extraktion von rns aus einem fixierten eingebetteten gewebe
EP2744916A4 (de) 2011-07-13 2015-06-17 Primeradx Inc Multimodale verfahren zur simultanen erkennung und quantifizierung mehrerer nukleinsäuren in einer probe
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
CN102533740B (zh) * 2011-09-07 2013-07-24 杭州艾迪康医学检验中心有限公司 人白血病融合基因bcr-abl的rt-pcr引物及其使用方法
CN104364390B (zh) 2011-10-14 2016-08-24 俄亥俄州立大学 与卵巢癌相关的方法和材料
WO2013070521A1 (en) * 2011-11-08 2013-05-16 Genomic Health, Inc. Method of predicting breast cancer prognosis
CN103145845A (zh) * 2011-12-06 2013-06-12 吉林圣元科技有限责任公司 Tat与人野生型P53融合蛋白在毕赤酵母中的表达
EP2790735A4 (de) 2011-12-13 2015-12-09 Ohio State Innovation Foundation Verfahren und zusammensetzungen im zusammenhang mit mir-21 und mir-29a, exosomerhemmung und krebsmetastasen
CN104685065B (zh) 2012-01-20 2017-02-22 俄亥俄州立大学 浸润性和预后的乳腺癌生物标志物标签
EP2823303A4 (de) 2012-02-10 2015-09-30 Raindance Technologies Inc Molekulardiagnostischer screeningtest
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
EA201492284A1 (ru) 2012-06-27 2015-11-30 Берг Ллк Применение маркеров в диагностике и лечении рака предстательной железы
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
US20140186468A1 (en) * 2012-12-07 2014-07-03 Susana Gonzalo Diagnosing subsets of triple-negative breast cancer
MX2015009260A (es) 2013-01-18 2015-10-15 Ellis Kline Regimen de glicosidasa selectiva para programacion inmunitaria y tratamiento del cancer.
CN104981697B (zh) 2013-02-11 2017-08-04 英丘伦有限责任公司 促染色质转录复合物(fact)在癌症中的用途
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
WO2014190090A1 (en) * 2013-05-21 2014-11-27 Dignity Health Genetic signature of vulnerability to inhibitors of base excision repair (ber) in cancer
US10181008B2 (en) 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2015048098A1 (en) 2013-09-24 2015-04-02 Washington University Diagnostic methods for infectious disease using endogenous gene expression
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
EP3143160B1 (de) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gensignaturen für krebsprognosen
CA2987389A1 (en) 2014-06-02 2015-12-10 Valley Health System Method and systems for lung cancer diagnosis
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
US10545136B2 (en) 2014-10-17 2020-01-28 Assistance Publique Hopitaux De Paris Methods for the monitoring and prognosis of a cancer
US10016159B2 (en) 2014-10-24 2018-07-10 Koninklijke Philips N.V. Determination of TGF-β pathway activity using unique combination of target genes
ES2857953T3 (es) 2014-10-24 2021-09-29 Koninklijke Philips Nv Pronóstico médico y predicción de la respuesta al tratamiento usando las actividades de múltiples rutas de señalización celular
EP3210144B1 (de) 2014-10-24 2020-10-21 Koninklijke Philips N.V. Medizinische prognose und vorhersage der behandlungsreaktion mithilfe der aktivitäten mehrerer zellsignalisierungspfade
EP3227687A4 (de) 2014-12-05 2018-10-24 Prelude, Inc. Dcis-wiederauftreten und invasiver brustkrebs
EP4242329A3 (de) 2014-12-08 2023-10-25 Berg LLC Verwendung von markern einschliesslich filamin a bei der diagnose und behandlung von prostatakrebs
AU2016302344A1 (en) 2015-08-06 2018-03-08 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
DK3334837T3 (da) 2015-08-14 2021-02-15 Koninklijke Philips Nv Vurdering af nfkb-cellulær signaleringsvejaktivitet under anvendelse af matematisk modellering af målgenekspression
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CA3026809A1 (en) 2016-06-21 2017-12-28 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
WO2018093797A1 (en) * 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
EP3461915A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären jak-stat1/2-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
EP3461916A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der zellulären jak-stat3-signalisierungspfadaktivität mittels mathematischer modellierung der zielgenexpression
EP3710008A4 (de) 2017-11-14 2021-08-25 The Schepens Eye Research Institute, Inc. Runx1-hemmung zur behandlung von proliferativer vitreoretinopathie und erkrankungen im zusammenhang mit der epithelial-mesenchymalen transition
EP3728630A4 (de) 2017-12-19 2021-11-17 The Wistar Institute Of Anatomy And Biology Zusammensetzungen und verfahren zur diagnose von lungenkrebs unter verwendung von genexpressionsprofilen
EP3502279A1 (de) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären mapk-ap 1-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
CN110045120A (zh) * 2018-01-15 2019-07-23 长庚医疗财团法人基隆长庚纪念医院 检测生物样品中wisp1的浓度在制备用于乳癌筛检及侦测复发的检测试剂盒及其应用
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
EP3850368A4 (de) 2018-09-14 2022-11-23 Prelude Corporation Verfahren zur auswahl zur behandlung von subjekten mit risiko auf invasiven brustkrebs
WO2020178399A1 (en) 2019-03-05 2020-09-10 Norwegian University Of Science And Technology (Ntnu) Breast cancer signature genes
EP4097479A4 (de) * 2020-01-30 2023-12-20 Arocell AB Vorhersage des überlebens von patienten
US12555649B2 (en) * 2020-10-09 2026-02-17 Worldwide Innovative Network Prediction method and gene signatures for the treatment of cancer
MX2023012434A (es) * 2021-04-21 2024-02-08 Apollomics Inc Diagnostico y tratamiento de cancer usando inhibidor de c-met.
EP4253567A1 (de) 2022-03-31 2023-10-04 OncoAssure Limited Verfahren zur vorhersage des risikos von aggressivem oder wiederkehrendem krebs

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US788019A (en) * 1904-06-29 1905-04-25 Charlie B Cady Hay fork and hook.
CA1252046A (en) 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US5563035A (en) * 1994-06-16 1996-10-08 The Board Of Trustees Of The Leland Stanford Junior University Estrogen receptor regulation and its uses
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
AU724107B2 (en) * 1997-01-31 2000-09-14 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin E
US6180333B1 (en) * 1997-05-15 2001-01-30 Thomas Jefferson University Determination of cyclin-dependent kinase inhibitor P27 levels as a prognostic factor in cancer patients
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6331396B1 (en) * 1998-09-23 2001-12-18 The Cleveland Clinic Foundation Arrays for identifying agents which mimic or inhibit the activity of interferons
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1159619A2 (de) * 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Verfahren zur diagnose und zum behandeln von brustkrebs
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
AU5789500A (en) * 1999-07-09 2001-01-30 Burnham Institute, The A method for determining the prognosis of cancer patients by measuring levels ofbag expression
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
CA2391805A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
CA2393136A1 (en) * 1999-11-30 2001-06-07 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051661A2 (en) * 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
NZ520095A (en) * 2000-01-13 2004-05-28 Genentech Inc Novel Stra6 polypeptides, nucleic acids, antibodies, compositions and methods of treatments for inhibiting tumor cell growth
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
EP1257664A4 (de) * 2000-01-28 2006-04-05 Althea Technologies Inc Verfahren zur analyse der genexpression
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
WO2001075159A2 (en) 2000-03-31 2001-10-11 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001280008A1 (en) * 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
AU2001278076A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
AR035541A1 (es) * 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
AU2002234799A1 (en) * 2000-12-08 2002-06-18 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
CA2440703A1 (en) 2001-01-24 2002-08-01 Protein Design Labs, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
EP1373896A2 (de) * 2001-03-12 2004-01-02 MonoGen, Inc. Auf zellen basierte nachweis und unterscheidung von krankheitszuständen
WO2002084560A1 (en) * 2001-04-06 2002-10-24 Florence Comite System and method for delivering integrated health care
CN1526025A (zh) * 2001-05-16 2004-09-01 ��˹��ŵ�� 作为预后和治疗靶标的乳腺癌中表达的基因
DK1410011T3 (da) * 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
US20040009489A1 (en) * 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
DK3115470T3 (en) 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20050216961A1 (en) 2002-03-28 2005-09-29 Delaney Allen D Cancer associated protein kinases and their uses
EP1365034A3 (de) 2002-05-21 2004-02-18 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren
EP1810034A4 (de) 2002-06-19 2008-06-25 Smithkline Beecham Corp Prädiktive marker in der krebstherapie
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US7767391B2 (en) * 2003-02-20 2010-08-03 Genomic Health, Inc. Use of intronic RNA to measure gene expression
CA2527285A1 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
DK1641810T4 (en) * 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
US20050221398A1 (en) 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
EP1737980A2 (de) * 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Genexpressionsmarker zur vorhersage des ansprechens auf chemotherapie
JP2006040014A (ja) 2004-07-28 2006-02-09 Matsushita Electric Ind Co Ltd 情報通信端末
US20090239214A1 (en) 2004-07-30 2009-09-24 Hongyue Dai Prognosis of breast cancer patients
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2006052731A2 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
WO2007057746A2 (en) 2005-05-27 2007-05-24 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP4369419B2 (ja) * 2005-12-09 2009-11-18 株式会社小松製作所 無人車両の誘導走行制御装置
US7888019B2 (en) * 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
CN101421600B (zh) * 2006-04-11 2011-11-30 萨索特兰公司 用于校准分布式纤维温度感测系统的方法和装置
US7569645B2 (en) * 2007-06-27 2009-08-04 Momentive Performance Materials Inc. Curable silyl-containing polymer composition containing paint adhesion additive
WO2009026128A2 (en) * 2007-08-16 2009-02-26 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
CA2723972A1 (en) 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options

Also Published As

Publication number Publication date
JP2013146277A (ja) 2013-08-01
EP1918386B1 (de) 2011-10-19
WO2003078662A1 (en) 2003-09-25
CA2992643C (en) 2019-06-18
HK1203568A1 (en) 2015-10-30
JP2013146279A (ja) 2013-08-01
JP5792765B2 (ja) 2015-10-14
EP3115470A1 (de) 2017-01-11
AU2003253986A1 (en) 2003-09-29
US20070141588A1 (en) 2007-06-21
US7838224B2 (en) 2010-11-23
EP1918386A1 (de) 2008-05-07
US20070141589A1 (en) 2007-06-21
US10241114B2 (en) 2019-03-26
EP2799555A1 (de) 2014-11-05
US20070059737A1 (en) 2007-03-15
JP4753741B2 (ja) 2011-08-24
US7858304B2 (en) 2010-12-28
US20100209920A1 (en) 2010-08-19
EP2241636A1 (de) 2010-10-20
DK2799555T3 (en) 2017-05-22
ES2685702T3 (es) 2018-10-10
US20070141587A1 (en) 2007-06-21
EP3115470B1 (de) 2018-07-18
DK1918386T3 (da) 2012-01-02
EP2261369B1 (de) 2014-05-14
JP2006129880A (ja) 2006-05-25
EP2261368A1 (de) 2010-12-15
ES2433992T3 (es) 2013-12-13
US20030225528A1 (en) 2003-12-04
HK1148032A1 (en) 2011-08-26
JP2005519624A (ja) 2005-07-07
HK1148034A1 (en) 2011-08-26
EP2261369A3 (de) 2011-05-04
DK2258872T3 (da) 2013-11-18
EP1918386B9 (de) 2012-08-08
US20070065845A1 (en) 2007-03-22
US7081340B2 (en) 2006-07-25
JP5461729B2 (ja) 2014-04-02
ES2616800T3 (es) 2017-06-14
EP2261369A2 (de) 2010-12-15
CA2478850C (en) 2018-02-27
US20070065846A1 (en) 2007-03-22
US8071286B2 (en) 2011-12-06
EP2258872A3 (de) 2011-05-04
JP2011250809A (ja) 2011-12-15
ES2374311T3 (es) 2012-02-15
EP2258872A2 (de) 2010-12-08
CA2478850A1 (en) 2003-09-25
JP5461730B2 (ja) 2014-04-02
EP2258872B1 (de) 2013-08-14
EP1918386A9 (de) 2008-07-09
HK1120567A1 (en) 2009-04-03
EP1488007A1 (de) 2004-12-22
EP2258873A2 (de) 2010-12-08
DK2261369T3 (da) 2014-07-28
US20080182255A1 (en) 2008-07-31
CA2992643A1 (en) 2003-09-25
EP1488007A4 (de) 2006-05-03
JP5373019B2 (ja) 2013-12-18
JP2013146278A (ja) 2013-08-01
DK3115470T3 (en) 2018-11-05
EP2799555B1 (de) 2017-02-22
EP2258873A3 (de) 2011-05-04
ES2486265T3 (es) 2014-08-18
AU2003253986A8 (en) 2003-09-29
WO2003078662A9 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
Van der Waal et al. Oral metastases: report of 24 cases
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
CY1111147T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
WO2004053066A3 (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
DE60107815D1 (de) Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
NO20014769L (no) Preparat for behandling og diagnostikk av brystcancer og fremgangsmater for anvendelse derav
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
ATE458049T1 (de) In prostatakrebs exprimiertes gen
AU2003217397A8 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
AR019288A1 (es) Procedimiento para detectar tejido canceroso
WO2003070889A3 (en) Prostate specific genes and the use thereof in design or therapeutics
WO2004066946A3 (en) Method for evaluating the efficacy of certain cancer treatments
WO2002099421A3 (en) Specific microarrays for breast cancer screening
ATE530668T1 (de) Verfahren und kits zur brustkrebsprognose
Ratajek-Gruda et al. Squamos cell carcinoma in the fornix of the oral vestibule
AU2003282069A8 (en) Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment
CY1116404T1 (el) Χρηση ιμικιμοδης για τη θεραπευτικη αγωγη δερματικων μεταστασεων οι οποιες προερχονται απο εναν ογκο καρκινου του μαστου
GB0120926D0 (en) Proteins,genes and their use for diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1918386

Country of ref document: EP